公开(公告)号：US20240294884A1

公开(公告)日：2024-09-05

申请号：US18663981

申请日：2024-05-14

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Jason DEHART ,  Selina KHAN ,  Vinod KRISHNA ,  Jenifer LUM ,  Christian MAINE ,  Barbara SANDERS ,  Manuel Alejandro SEPULVEDA ,  Patrick WILKINSON ,  Roland ZAHN

IPC: C12N7/00 ,  A61K39/00 ,  A61K45/06 ,  C12N15/86

CPC classification number: C12N7/00 ,  A61K45/06 ,  C12N15/86 ,  A61K2039/505 ,  C12N2750/14111

Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.

公开(公告)号：US20210222133A1

公开(公告)日：2021-07-22

申请号：US17097458

申请日：2020-11-13

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Jason DEHART ,  Selina KHAN ,  Vinod KRISHNA ,  Jenifer LUM ,  Christian MAINE ,  Barbara SANDERS ,  Manuel Alejandro SEPULVEDA ,  Patrick WILKINSON ,  Roland ZAHN

IPC: C12N7/00 ,  C12N15/86 ,  A61K45/06

Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.

公开(公告)号：US20240262921A1

公开(公告)日：2024-08-08

申请号：US18643356

申请日：2024-04-23

Applicant: Janssen Biotech, Inc.

Inventor： Ricardo ATTAR ,  Rajkumar Ganesan ,  Francois Gaudet ,  Bradley J. Heidrich ,  Carmen Baca Jones ,  John Lee ,  Yingzhe Li ,  Sanjaya Singh ,  Sathya Venkataramani

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.

公开(公告)号：US20170210799A1

公开(公告)日：2017-07-27

申请号：US15409630

申请日：2017-01-19

Applicant: JANSSEN BIOTECH, INC.

Inventor： Glenn Mark ANDERSON ,  Eric T. BALDWIN ,  Benjamin HARMAN ,  Rosa M.F. CARDOSO ,  Jennifer F. NEMETH-SEAY ,  Ricardo ATTAR ,  Francois GAUDET ,  Yingzhe LI ,  Jinquan LUO ,  Ronan MCDAID ,  Steven C. POMERANTZ ,  Susan H. TAM ,  Alexey TEPLYAKOV ,  Sheng-Jiun WU

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: Provided herein are isolated antibodies that immunospecifically bind to ROR1, bispecific antibodies comprising an antigen-binding site that immunospecifically binds to ROR1 and an antigen-binding site that immunospecifically binds to CD3, and methods of using the same.